Peptide record

TPDB25817

Antibacterial Anticancer Antiviral Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25817
Antibacterial Anticancer Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard-residue multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, AI4AVP, dbAMP 3.0, and other sources, with an available 3D structural model.
Sequence
SWLRDIWDWICEVLSDFK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C109H155N25O29S1
ANQGHMPTY
DW
2311.64
3.97
2
4
9
-2
1.40
-0.033
102.78
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
16500
7.14
3
Residue Composition
number
0
A
1
R
0
N
3
D
1
C
1
E
0
Q
0
G
0
H
2
I
2
L
1
K
0
M
1
F
0
P
2
S
0
T
3
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 3 C: 1 E: 1 Q: 0 G: 0 H: 0 I: 2 L: 2 K: 1 M: 0 F: 1 P: 0 S: 2 T: 0 W: 3 Y: 0 V: 1
Chemical Descriptors
18 reviewed residue count
C109H155N25O29S1 sequence-only estimate (linear, free termini)
2311.64 sequence-only estimate (linear, free termini)
3.97 sequence-only estimate (linear, free termini)
-2 sequence-only estimate (linear, free termini)
1.40 sequence-only estimate (linear, free termini)
-0.033 sequence-only estimate (linear, free termini)
Evidence Records 2 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
3.46 µM
Hemolytic Cytotoxic
0% Hemolysis | 3.46 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Rational design of peptides with anti-HCV/HIV activities and enhanced specificity. | Chem Biol Drug Des | 2011
Evidence 2 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis